Relmada Therapeutics annual working capital
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics Working Capital Growth & History (RLMD)
Relmada Therapeutics's working capital was $87.6M for fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $87.6M | $52.0M | +146.60% |
| 2024 | 2024-12-31 | $35.5M | −$49.8M | −58.38% |
| 2023 | 2023-12-31 | $85.3M | −$55.1M | −39.24% |
| 2022 | 2022-12-31 | $140.4M | −$67.8M | −32.58% |
| 2021 | 2021-12-31 | $208.2M | $102.8M | +97.44% |
| 2020 | 2020-12-31 | $105.5M | −$10.0M | −8.67% |
| 2019 · Dec 31 | 2019-12-31 | $115.5M | — | — |
| 2019 · Jun 30 | 2019-06-30 | $7.4M | $10.5M | — |
| 2018 | 2018-06-30 | −$3.2M | −$4.3M | — |
| 2017 | 2017-06-30 | $1.1M | −$5.1M | −82.39% |
| 2016 | 2016-06-30 | $6.2M | −$2.1M | −25.61% |
| 2015 | 2015-06-30 | $8.4M | $9.4M | — |
| 2014 | 2014-06-30 | −$1.0M | — | — |
| 2013 · Dec 31 | 2013-12-31 | −$17.9M | — | — |
| 2013 · Aug 31 | 2013-08-31 | −$15,207 | −$26,565 | — |
| 2012 · Aug 31 | 2012-08-31 | $11,358 | — | — |
Relmada Therapeutics quarterly working capital
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q4.13
Q1.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $211.6M | $195.7M | +1225.96% |
| Q1 2026 | 2026-03-31 | $222.5M | $200.0M | +891.94% |
| Q4 2025 | 2025-12-31 | $87.6M | $52.0M | +146.60% |
| Q3 2025 | 2025-09-30 | $9.7M | −$38.0M | −79.70% |
| Q2 2025 | 2025-06-30 | $16.0M | −$45.5M | −74.02% |
| Q1 2025 | 2025-03-31 | $22.4M | −$49.6M | −68.85% |
| Q4 2024 | 2024-12-31 | $35.5M | −$49.8M | −58.38% |
| Q3 2024 | 2024-09-30 | $47.6M | −$53.1M | −52.71% |
| Q2 2024 | 2024-06-30 | $61.4M | −$49.9M | −44.80% |
| Q1 2024 | 2024-03-31 | $72.0M | −$53.4M | −42.60% |
| Q4 2023 | 2023-12-31 | $85.3M | −$55.1M | −39.24% |
| Q3 2023 | 2023-09-30 | $100.7M | −$65.6M | −39.47% |
| Q2 2023 | 2023-06-30 | $111.3M | −$85.5M | −43.45% |
| Q1 2023 | 2023-03-31 | $125.4M | −$84.9M | −40.37% |
| Q4 2022 | 2022-12-31 | $140.4M | −$67.8M | −32.58% |
| Q3 2022 | 2022-09-30 | $166.3M | $93.7M | +128.98% |
| Q2 2022 | 2022-06-30 | $196.8M | $100.0M | +103.36% |
| Q1 2022 | 2022-03-31 | $210.4M | $119.3M | +131.03% |
| Q4 2021 | 2021-12-31 | $208.2M | $102.8M | +97.44% |
| Q3 2021 | 2021-09-30 | $72.6M | −$49.4M | −40.50% |
| Q2 2021 | 2021-06-30 | $96.8M | −$35.3M | −26.72% |
| Q1 2021 | 2021-03-31 | $91.1M | −$21.9M | −19.41% |
| Q4 2020 | 2020-12-31 | $105.5M | −$10.0M | −8.67% |
| Q3 2020 | 2020-09-30 | $122.1M | — | — |
| Q2 2020 | 2020-06-30 | $132.1M | $124.7M | +1690.18% |
| Q1 2020 · Mar 31 | 2020-03-31 | $113.0M | $112.8M | +56259.26% |
| Q4 2019 · Dec 31 | 2019-12-31 | $115.5M | $114.3M | +9791.65% |
| Q4 2019 · Jun 30 | 2019-06-30 | $7.4M | $10.5M | — |
| Q3 2019 | 2019-03-31 | $200,471 | $1.3M | — |
| Q2 2019 | 2018-12-31 | $1.2M | −$499,490 | −29.96% |
| Q1 2019 | 2018-09-30 | −$5.8M | −$7.6M | — |
| Q4 2018 | 2018-06-30 | −$3.2M | −$4.3M | — |
| Q3 2018 | 2018-03-31 | −$1.1M | −$3.1M | — |
| Q2 2018 | 2017-12-31 | $1.7M | −$2.2M | −57.06% |
| Q1 2018 | 2017-09-30 | $1.8M | −$3.0M | −62.27% |
| Q4 2017 | 2017-06-30 | $1.1M | −$5.1M | −82.39% |
| Q3 2017 | 2017-03-31 | $2.0M | −$7.4M | −78.50% |
| Q2 2017 | 2016-12-31 | $3.9M | −$7.0M | −64.29% |
| Q1 2017 | 2016-09-30 | $4.8M | −$8.6M | −64.50% |
| Q4 2016 | 2016-06-30 | $6.2M | −$2.1M | −25.61% |
| Q3 2016 | 2016-03-31 | $9.4M | $6.8M | +266.29% |
| Q2 2016 | 2015-12-31 | $10.9M | $6.2M | +133.43% |
| Q1 2016 | 2015-09-30 | $13.4M | $34.1M | — |
| Q4 2015 | 2015-06-30 | $8.4M | $9.4M | — |
| Q3 2015 | 2015-03-31 | $2.6M | — | — |
| Q2 2015 | 2014-12-31 | $4.7M | $22.5M | — |
| Q1 2015 | 2014-09-30 | −$20.7M | — | — |
| Q4 2014 | 2014-06-30 | −$1.0M | — | — |
| Q1 2014 · Feb 28 | 2014-02-28 | −$32,405 | −$30,597 | — |
| Q4 2013 · Dec 31 | 2013-12-31 | −$17.9M | — | — |
| Q1 2014 · Nov 30 | 2013-11-30 | −$29,431 | — | — |
| Q4 2013 · Aug 31 | 2013-08-31 | −$15,207 | −$26,565 | — |
| Q2 2013 | 2013-05-31 | −$22,993 | — | — |
| Q1 2013 | 2013-02-28 | −$1,808 | — | — |
| Q4 2012 | 2012-08-31 | $11,358 | — | — |
Relmada Therapeutics working capital trends
Over the last five fiscal years, Relmada Therapeutics's working capital decreased from $105.5M to $87.6M, a change of −$17.9M. The latest reported quarter, Q2 2026, shows $211.6M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗